The Galena Biopharma Inc. (GALE) Receives Buy Rating from Maxim Group

Josh Kim
December 15, 2016

The company's market cap is $60.53 million. Galena Biopharma, Inc. stock trades in the range of $1.84 to $2.19 before the earnings release. (NASDAQ:APOL) topped its 52-week high price of $9.66 on Dec 13, 2016 and 52-Week Low Price of $6.31 on Jan 11, 2016. They now have a United States dollars 0.4 price target on the stock. The price to earnings ratio for the company is 1.89 with a beta of 0.59. The analysts estimated EPS for the higher end at 0.16 and lower end at 0.02 while the year ago reported earnings per share was 0.08. (NASDAQ:APOL) reported its EPS in the last quarter as $0.21/Share Topping the analyst estimate of $-0.05/Share by the difference of $0.26. (GALE) managed to surpass quarterly earnings per share estimates in 6 of the trailing twelve fiscal quarters, and has a positive trend with an average surprise of 50%. (NASDAQ:APOL) is now showing -34.5% EPS growth this Quarter. The Mean and Low price Targets are $9.5 and $8, respectively. The share price is now 4.71 percent versus its SMA20, 19.79 percent versus its SMA50, and 93.23 percent versus its SMA200. (GALE) is getting weaker by the somewhat negative sentiment (2.30 on a 5-point scale) that sell-side analysts have provided concerning it. Brokerage firms on the average advocate the company shares as Buy.

Finally, Vanguard Group Inc. boosted its position in shares of Galena Biopharma by 2.3% in the second quarter. According to their observations and findings, the stock could provide a high EPS of $0.19/share and a Low EPS of $0.19/share. (NASDAQ:PDLI). These ratios are important while doing valuation of the company or the shares of the company. The volume of the company in the last trading session was 3.22 Million. The stock's market capitalization is 22.78M. They now have a Dollars 1.5 price target on the stock. The company's stock is moving with the distance from SMA 50 of -32.56 Percent while the distance from 200-day simple moving average for the stock is -36.49 percent. The stock is now has its Return on Assets (ROA) value of 16.1 Percent. The Company's development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Weekly Volatility is 6.57 percent and the Monthly Volatility is 6.79 percent. Three analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. BlackRock Fund Advisors now owns 4,766,441 shares of the biotechnology company's stock worth $2,222,000 after buying an additional 42,824 shares during the last quarter. The company has a Low Price Target of $3 and the Mean Target of $3.5, according to the Brokers.

Girl, 16, 'was tortured and starved to death by her own parents '
Prior to the teen's death, another neighbor, Tiana Curtis told of having reached out to The Iowa Department of Human Services . Police only began investigating the family after the emergency services were called when Natalie was suffering cardiac arrest.

For the Current Quarter, 2 analyst are projecting the mean EPS to be $0.19/share. BlackRock Fund Advisors boosted its position in shares of Galena Biopharma by 0.9% in the second quarter.

Other reports by MyHealthBowl

Discuss This Article